{"title":"三联疗法治疗前列腺癌根治性前列腺切除术后多器官转移复发疗效显著1例","authors":"Shuhei Kusano, Shohei Tobu, Minika Yukimoto, Yukako Yamaguchi, Yuka Kakinoki, Akihiro Maeda, Maki Kawasaki, Hiroaki Kakinoki, Mitsuru Noguchi","doi":"10.1002/iju5.70082","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>We report a case in which triplet therapy demonstrated efficacy for multiple metastatic recurrences following radical prostatectomy.</p>\n </section>\n \n <section>\n \n <h3> Case Presentation</h3>\n \n <p>A 70-year-old man with relapsed metastatic castration-sensitive prostate cancer (mCSPC) following radical prostatectomy (Gleason 9, pT3bN1M0) presented with rectal involvement and extensive lymph node and bone metastases, as evidenced by a markedly elevated PSA level of 59.57 ng/mL. He received triplet therapy consisting of androgen deprivation therapy (ADT) with degarelix, darolutamide (1200 mg/day), and docetaxel (70 mg/m<sup>2</sup>). This combination led to a complete PSA response, dropping below the detection limit (< 0.006 ng/mL). At 24 months post-treatment, the patient remained in a stable condition without any signs of PSA recurrence.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This case highlights the potential of triplet therapy as a highly effective treatment strategy for high-risk mCSPC patients who experience recurrence after initial local therapy.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 5","pages":"517-520"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70082","citationCount":"0","resultStr":"{\"title\":\"A Case of Triplet Therapy Showing Remarkable Efficacy for Multiorgan Metastatic Recurrence After Radical Prostatectomy in Prostate Cancer\",\"authors\":\"Shuhei Kusano, Shohei Tobu, Minika Yukimoto, Yukako Yamaguchi, Yuka Kakinoki, Akihiro Maeda, Maki Kawasaki, Hiroaki Kakinoki, Mitsuru Noguchi\",\"doi\":\"10.1002/iju5.70082\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>We report a case in which triplet therapy demonstrated efficacy for multiple metastatic recurrences following radical prostatectomy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Case Presentation</h3>\\n \\n <p>A 70-year-old man with relapsed metastatic castration-sensitive prostate cancer (mCSPC) following radical prostatectomy (Gleason 9, pT3bN1M0) presented with rectal involvement and extensive lymph node and bone metastases, as evidenced by a markedly elevated PSA level of 59.57 ng/mL. He received triplet therapy consisting of androgen deprivation therapy (ADT) with degarelix, darolutamide (1200 mg/day), and docetaxel (70 mg/m<sup>2</sup>). This combination led to a complete PSA response, dropping below the detection limit (< 0.006 ng/mL). At 24 months post-treatment, the patient remained in a stable condition without any signs of PSA recurrence.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>This case highlights the potential of triplet therapy as a highly effective treatment strategy for high-risk mCSPC patients who experience recurrence after initial local therapy.</p>\\n </section>\\n </div>\",\"PeriodicalId\":52909,\"journal\":{\"name\":\"IJU Case Reports\",\"volume\":\"8 5\",\"pages\":\"517-520\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70082\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IJU Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/iju5.70082\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.70082","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
A Case of Triplet Therapy Showing Remarkable Efficacy for Multiorgan Metastatic Recurrence After Radical Prostatectomy in Prostate Cancer
Introduction
We report a case in which triplet therapy demonstrated efficacy for multiple metastatic recurrences following radical prostatectomy.
Case Presentation
A 70-year-old man with relapsed metastatic castration-sensitive prostate cancer (mCSPC) following radical prostatectomy (Gleason 9, pT3bN1M0) presented with rectal involvement and extensive lymph node and bone metastases, as evidenced by a markedly elevated PSA level of 59.57 ng/mL. He received triplet therapy consisting of androgen deprivation therapy (ADT) with degarelix, darolutamide (1200 mg/day), and docetaxel (70 mg/m2). This combination led to a complete PSA response, dropping below the detection limit (< 0.006 ng/mL). At 24 months post-treatment, the patient remained in a stable condition without any signs of PSA recurrence.
Conclusion
This case highlights the potential of triplet therapy as a highly effective treatment strategy for high-risk mCSPC patients who experience recurrence after initial local therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
